1. Kessler MA, Yang M, Gollomp KL, et al. The human tyrosine hydroxylase gene promoter. Brain Res Mol Brain Res 2003 112:8-23.
2. Herman JP, Abrous ND. Dopaminergic neural grafts after fifteen years: results and perspectives. Prog Neurobiol 1994 44:1-35.
3. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci 1996 19:102-9.
5. Horellou P, Brundin P, Kalén P, et al. In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. Neuron 1990 5:393-402.
8. Horellou P, Vigne E, Castel MN, et al. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson’s disease. Neuroreport 1994 6:49-53.
10. Karaöz E, Demircan PC, Sağlam O, et al. Human dental pulp stem cells demonstrate better neural and epithelial stem cell properties than bone marrow-derived mesenchymal stem cells. Histochem Cell Biol 2011 136:455-73.
11. Lu L, Zhao C, Liu Y, et al. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson’s disease. Brain Res Brain Res Protoc 2005 15:46-51.
13. Karaoz E, Ayhan S, Okçu A, et al. Bone marrow-derived mesenchymal stem cells co-cultured with pancreatic islets display β cell plasticity. J Tissue Eng Regen Med 2011 5:491-500.
14. Karaoz E, Aksoy A, Ayhan S, et al. Characterization of mesenchymal stem cells from rat bone marrow: ultrastructural properties, differentiation potential and immunophenotypic markers. Histochem Cell Biol 2009 132:533-46.
16. Su P, Loane C, Politis M. The use of stem cells in the treatment of Parkinson’s disease. Insciences J 2001 1:136-56.
17. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 2004 10 Suppl:S42-50.
18. Ko TL, Fu YY, Shih YH, et al. A high-efficiency induction of dopaminergic cells from human umbilical mesenchymal stem cells for the treatment of hemiparkinsonian rats. Cell Transplant 2015 24:2251-62.
20. Jin GZ, Cho SJ, Lee YS, et al. Intrastriatal grafts of mesenchymal stem cells in adult intact rats can elevate tyrosine hydroxylase expression and dopamine levels. Cell Biol Int 2009 34:135-40.
21. Chao YX, He BP, Tay SS. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson’s disease. J Neuroimmunol 2009 216:39-50.
22. Blandini F, Cova L, Armentero MT, et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 2010 19:203-17.
23. Zhang S, Zou Z, Jiang X, et al. The therapeutic effects of tyrosine hydroxylase gene transfected hematopoetic stem cells in a rat model of Parkinson’s disease. Cell Mol Neurobiol 2008 28:529-43.
24. Zou Z, Jiang X, Zhang W, et al. Efficacy of Tyrosine Hydroxylase gene modified neural stem cells derived from bone marrow on Parkinson’s disease--a rat model study. Brain Res 2010 1346:279-86.
25. Bertani N, Malatesta P, Volpi G, et al. Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray. J Cell Sci 2005 118(Pt 17):3925-36.
26. Ye M, Wang XJ, Zhang YH, et al. Therapeutic effects of differentiated bone marrow stromal cell transplantation on rat models of Parkinson’s disease. Parkinsonism Relat Disord 2007 13:44-9.
28. Zhao LR, Duan WM, Reyes M, et al. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002 174:11-20.
29. Azadi S, Johnson LE, Paquet-Durand F, et al. CNTF+BDNF treatment and neuroprotective pathways in the rd1 mouse retina. Brain Res 2007 1129:116-29.
30. Karaoz E, Kabatas S, Duruksu G, et al. Reduction of lesion in injured rat spinal cord and partial functional recovery of motility after bone marrow derived mesenchymal stem cell transplantation. Turk Neurosurg 2012 22:207-17.
34. Bresnahan WA, Boldogh I, Ma T, et al. Cyclin E/Cdk2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle. Cell Growth Differ 1996 7:1283-90.
35. Matsumoto Y, Maller JL. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Science 2004 306:885-8.
36. Cohen B, Shimizu M, Izrailit J, et al. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat 2010 123:113-24.